Lumisys president Philip Berman has added the title of CEO, assuming that post from chairman Douglas DeVivo. Berman, who came to Lumisys in November when the company acquired CompuRad, will spearhead the company's entrée into the computed
Lumisys president Philip Berman has added the title of CEO, assuming that post from chairman Douglas DeVivo. Berman, who came to Lumisys in November when the company acquired CompuRad, will spearhead the company's entrée into the computed radiography market (SCAN 5/13/98).
Berman's appointment comes soon after other management moves by the company. COO and CFO Craig Klosterman has left the company to join Informatica, a private software company. Replacing Klosterman as CFO is vice president of finance Dean MacIntosh. Also, the company has hired Duncan Moffat for the newly created post of vice president of operations.
In other Lumisys news, the company has begun a road show to commemorate the launch of its ACR-2000 desktop computed radiography unit, which Lumisys plans to sell through the same network of OEMs that market its film digitizers. Vice president of channel development and sales Scott Evers is traveling around the U.S. in a new yellow Volkswagen Beetle to demonstrate the unit to clinics, hospitals, OEMs, VARs, and systems integrators. The trip will conclude at this year's Radiological Society of North America meeting, with commercial deliveries expected to begin in early 1999.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study: Black Patients Less Likely Than Others to Receive MRI Assessment of Cognitive Impairment
November 27th 2023In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.